GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » Cost of Goods Sold

Baxalta (Baxalta) Cost of Goods Sold : $2,525 Mil (TTM As of Mar. 2016)


View and export this data going back to 2015. Start your Free Trial

What is Baxalta Cost of Goods Sold?

Baxalta's cost of goods sold for the three months ended in Mar. 2016 was $710 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2016 was $2,525 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Baxalta's Gross Margin % for the three months ended in Mar. 2016 was 54.13%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Baxalta's Inventory Turnover for the three months ended in Mar. 2016 was 0.32.


Baxalta Cost of Goods Sold Historical Data

The historical data trend for Baxalta's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta Cost of Goods Sold Chart

Baxalta Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Cost of Goods Sold
2,240.00 2,329.00 2,443.00 2,386.00

Baxalta Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 571.00 501.00 633.00 681.00 710.00

Baxalta Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,525 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxalta  (NYSE:BXLT) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Baxalta's Gross Margin % for the three months ended in Mar. 2016 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(1548 - 710) / 1548
=54.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Baxalta's Inventory Turnover for the three months ended in Mar. 2016 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Baxalta Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Baxalta's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxalta (Baxalta) Business Description

Traded in Other Exchanges
N/A
Address
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Executives
Gail D Fosler director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool officer: See Remarks C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson officer: EVP and President, Biosimilars C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek officer: EVP and President, Oncology 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards officer: SVP and General Counsel C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach officer: EVP. CFO and COO C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law officer: EVP & Head of Human Resources C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii director BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth director C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson director, officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921

Baxalta (Baxalta) Headlines

From GuruFocus

Keeley Funds Comments on Baxalta Inc.

By Holly LaFon Holly LaFon 02-03-2016

Tweedy Browne Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-27-2016

Baxalta: A Rare Undervalued Biopharmaceutical Company

By Ben Reynolds Ben Reynolds 07-23-2015

Jeff Auxier Sells Precision Castparts, AT&T, Microsoft

By Tiziano Frateschi Tiziano Frateschi 06-23-2016

Third Avenue Buys Baxter Spin-Off

By Kyle Ferguson Kyle Ferguson 01-17-2016

Is Baxalta a Good Spin-Off Opportunity?

By Raman Minhas Raman Minhas 10-15-2015

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 03-29-2016

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 12-10-2015

Undervalued Baxalta Shares Target of Acquisition by Shire Plc

By Ben Reynolds Ben Reynolds 08-05-2015